Fragile X Syndrome;Síndrome de X Frágil

Colombia Medica

Volumn 45, Issue 4, 2014, Pages 190-198

  Saldarriaga, Wilmar ^a   Tassone, Flora ^b   González Teshima, Laura Yuriko ^a   Forero Forero, Jose Vicente ^a   Ayala Zapata, Sebastián ^a   Hagerman, Randi ^c  

^a UNIVERSIDAD DEL VALLE   (Colombia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fragile X Mental Retardation Protein; Fragile X Syndrome; Genetic counselling; Intellectual disability; Review; Therapeutics

Indexed keywords

2 METHYL 6 PHENYLETHYNYLPYRIDINE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AMPA RECEPTOR; AMPHETAMINE; ARIPIPRAZOLE; BUTYRIC ACID; CLONIDINE; DNA METHYLTRANSFERASE; FOLIC ACID; GELATINASE B; GUANFACINE; HISTONE DEACETYLASE; LEVACECARNINE; LITHIUM; MESSENGER RNA; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; METHYLPHENIDATE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLIGIN; SERTRALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; FMR1 PROTEIN, HUMAN; FRAGILE X MENTAL RETARDATION PROTEIN;

ALLELE; ATAXIA; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); FRAGILE X MENTAL RETARDATION 1 GENE; FRAGILE X SYNDROME; GENE; GENOMICS; HERITABILITY; HUMAN; INHERITANCE; KARYOTYPE; KLINEFELTER SYNDROME; MUTATION; OVARY INSUFFICIENCY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRADER WILLI SYNDROME; RECURRENCE RISK; REVIEW; RNA TRANSLATION; SOTOS SYNDROME; SOUTHERN BLOTTING; TRINUCLEOTIDE REPEAT; X CHROMOSOME; ANIMAL; CHILD; DNA METHYLATION; FEMALE; GENETICS; MALE; PROMOTER REGION; SEX DIFFERENCE;

ANIMALS; BLOTTING, SOUTHERN; CHILD; DNA METHYLATION; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEX FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84921919410     PISSN: 01208322     EISSN: 16579534     Source Type: Journal    
DOI: 10.25100/cm.v45i4.1810     Document Type: Review

References (61)

1. Martin J P, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943; 6(3-4): 154–7.
2. Hagerman RJ, Hagerman PJ. Fragile X Syndrome. 3. Baltimore: The John Hopkins University Press; 2002.
3. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012; 122(12): 4314–22.
4. Liu Y, Winarni T, Zhang L, Tassone F, Hagerman R. Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet. 2013; 84: 74–7.
5. Hall D, Tassone F, Klepitskaya O, Leehey M. Fragile X associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012; 27(2): 296–300.
6. Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence of Fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009; 85: 503–14.
7. Hirst MC, Knight SJ, Christodoulou Z, Grewal PK, Fryns J P, Davies KE. Origins of the fragile X syndrome mutation. J Med Genet. 1993; 30(8): 647–50.
8. Gardeazabal AG. El divino. Bogota: Plaza Janes; 1986.
9. Payan C, Saldarriaga W, Isaza C, Alzate A. Estudio foco endémico de retardo mental en Ricaurte Valle. Acta Biológica Colombiana. 2001; 6(2): 88.
10. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 2013; 12(8): 786–98.
11. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009; 11(4): 324–9.
12. Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012; 4(12): 1–113.
13. Center for Disease Control and Prevention. Fragile X syndrome (FXS). Accessed 20 November 2014. Available from: http://www.cdc.gov/ncbddd/fxs/index.html.
14. Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato U, et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet. 2005; 14(2): 267–77.
15. Pieretti M, Zhang F P, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991; 66(4): 817–22.
16. Naumann A, Hochstein N, Weber S, Fanning E, Doerfler W. A distinct DNA-methylation boundary in the 5'-upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet. 2009; 85(5): 606–16.
17. Stöger R, Kajimura TM, Brown WT, Laird CD. Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum Mol Genet. 1997; 6(11): 1791–801.
18. Malter HE, Iber JC, Willemsen R, de Graaf E, Tarleton JC, Leisti J, et al. Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet. 1997; 15(2): 165–9.
19. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992; 1(6): 397–400.
20. Kniffn CL, Jackson JF. Fragile x mental retardation syndrome. Accessed: 20 November 2014. Available from: http://omim.org/clinicalSynopsis/300624?search=fragilexhighlight=x fragile.
21. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell. 1993; 74(2): 291–8.
22. Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science. 1993; 262(5133): 563–6.
23. Darnell JC, Van Driesche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247–61.
24. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, et al. Microarray identifcation of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001; 107(4): 477–87.
25. Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience. 2003; 120(4): 1005–17.
26. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27(7): 370–7.
27. Gatto CL, Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. Front Synaptic Neurosci. 2010; 2: 4.
28. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991; 65(5): 905–14.
29. Yrigollen CM, Martorell L, Durbin-Johnson B, Naudo M, Genoves J, Murgia A, et al. AGG interruptions and maternal age affect FMR1 CGG repeat allele stability during transmission. J Neurodev Disord. 2014; 6(1): 1–11.
30. Yrigollen CM, Durbin-Johnson B, Gane L, Nelson DL, Hagerman R, Hagerman PJ, et al. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genetics Med. 2012; 14(8): 729–36.
31. Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman PJ, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn. 2009; 11(4): 306–10.
32. Nolin SL, Brown WT, Glicksman A, Houck GE, Gargano AD, Sullivan A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet. 2003; 72(2): 454–64.
33. Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane L W, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord. 2007; 22(14): 2018–2030.
34. Seltzer MM, Baker M W, Hong J, Maenner M, Greenberg J, Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet. 2012; 159B(5): 589–97.
35. Bourgeois JA, Cogswell JB, Hessl D, Zhang L, Ono MY, Tassone F, et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry. 2007; 29(4): 349–56.
36. Martin JR, Arici A. Fragile X and reproduction. Curr Opin Obstet Gynecol. 2008; 20(3): 216–20.
37. Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem. 2010; 56: 399–408.
38. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008; 10: 43–9.
39. Chen L, Hadd A, Sah S, Filipovic-Sadic S, Krosting J, Sekinger E, et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J Mol Diagn. 2010; 12: 589–600.
40. Firth H V, Hurst JA, Hall JG. Oxford Desk Reference? Oxford: Oxford University Press; 2005.
41. O'Neil MJF, Jackson JF. SOTOS SYNDROME 1 SOTOS1. Accessed: 20 November 2014. Available from: http://omim.org/cli nicalSynopsis/117550?search=highlight=sotos.
42. Hamosh A, Jackson JF. PRADER-WILLI SYNDROME PWS. Accessed: 20 November 2014. Available from: http://omim.org/clinicalSynopsis/176270?search=praderhighlight=prader.
43. Rueda JR, Ballesteros J, Guillen V, Tejada MI, Solà I. Folic acid for fragile X syndrome. Cochrane database Syst Rev. 2011;(5):CD008476.
44. Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem. 2003; 278(30): 27586–92.
45. Tabolacci E, De Pascalis I, Accadia M, Terracciano A, Moscato U, Chiurazzi P, et al. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics. 2008; 18(8): 738–41.
46. Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010; 152A(6): 1420–7.
47. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123(1): 378–90.
48. Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009; 5: 145–50.
49. Su T, Fan H-X, Jiang T, Sun W-W, Den W-Y, Gao M-M, et al. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology. 2011; 215(2): 291–300.
50. Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013; 161A(8): 1897–1903.
51. Bilousova T V, Dansie L, Ngo M, Aye J, Charles JR, Ethell D W, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009; 46(2): 94–102.
52. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol. 2008; 180(5): 1021–35.
53. Wang X, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley G W. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci U S A. 2008; 105(49): 19520–5.
54. Dziembowska M, Milek J, Janusz A, Rejmak E, Romanowska E, Gorkiewicz T, et al. Activity-dependent local translation of matrix metalloproteinase-9. J Neurosci. 2012; 32(42): 14538–47.
55. Leigh MJS, Nguyen D V, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013; 34(3): 147–55.
56. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: A retrospective chart review. Autism Res Treat. 2012; 2012: 104317.
57. Moskowitz LJ, Carr EG, Durand VM. Behavioral intervention for problem behavior in children with fragile X syndrome. Am J Intellect Dev Disabil. 2011; 116(6): 457–8.
58. Turk J. Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry. 2011; 24(5): 387–97.
59. Dew-Hughes D. Educating children with fragile X syndrome. Florence: Routledge; 2003.
60. Dyer-Friedman J, Glaser B, Hessl D, Johnston C, Huffman LC, Taylor A, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. J Am Acad Child Adolesc Psychiatry. 2002; 41(3): 237–44.
61. Hessl D, Dyer-Friedman J, Glaser B, Wisbeck J, Barajas RG, Taylor A, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics. 2001; 108(5): E88.